Alhassen, Ziad http://orcid.org/0000-0001-6734-253X
Vali, Payam
Guglani, Lokesh
Lakshminrusimha, Satyan http://orcid.org/0000-0001-6098-2155
Ryan, Rita M.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R03 HD09299-01, 5R01 HD072929-08)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 13 November 2019
Revised: 22 May 2020
Accepted: 22 July 2020
First Online: 4 August 2020
Compliance with ethical standards
:
: PV is supported by NIH grant (1R03HD09299-01). SL is supported by NIH grant (5R01HD072929-08). ZA, LG, and RMR have no financial relationships to disclose relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. The use of antenatal betamethasone, diuretics and beta-agonists are not approved by the FDA in the prevention or treatment of TTN.
: Understand the pathophysiology that underlines Transient Tachypnea of Newborn (TTN). Recognize the clinical manifestations of TTN and the imaging modalities that may help in the diagnosis of TTN. Understand the benefits in providing Continuous Positive Airway Pressure (CPAP) for TTN. Recognize the possible long-term association of TTN with wheezing-related syndromes.
: It can be challenging to diagnose TTN and identify patients who may be at greatest risk of respiratory deterioration. Optimal management has not been established, and caring for patients with TTN, particularly at community hospitals, can be difficult. Increasing knowledge of the pathophysiology leads to improved therapeutic options.
: Define the molecular mechanisms involved in lung fluid clearance. Identify the clinical symptoms and signs, radiologic findings and risk factors associated with TTN. List the differential diagnosis of TTN. Explain the different treatment options for TTN.